EHA 2017 | Is obinutuzumab our key to improving the treatment of FL?
Wolfgang Hiddemann, MD, PhD, from Ludwig-Maximilians University, Munich, Germany, discusses current improvements in the treatment of follicular lymphoma, namely the combination of novel anti-CD20 monoclonal antibodies, such as obinutuzumab, with chemotherapy. Referencing a current Phase I/II trial (NCT02596971), Prof. Hiddemann explains that obinutuzumab may represent the next step forward in keeping patients longer in remission due to its superiority to rituximab, but notes that patients who received the drug with bendamustine suffered from adverse events, likely due to suppression of T-helper cells. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
Get great new content delivered to your inboxSign up